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Background/aim: Elderly patients are at high risk from drug–drug interactions (DDIs). This study evaluates the potential DDIs in
Turkish elderly patients at a primary health care outpatient clinic.
Materials and methods: Online database systems were used to examine DDIs on the prescriptions of patients (n = 1206). The clinical
severity of DDIs was classified by the Lexi-Interact Online database.
Results: Of the 5059 prescriptions, 33% were found to have DDIs. We detected 29 (0.9%) A, 380 (11.8%) B, 2494 (77.7%) C, 289 (9%) D,
and 18 (0.6%) X risk rating category DDIs among the prescriptions. Prescriptions of female patients and patients aged between 65 and
72 years showed significantly higher number of DDIs. The frequency of DDIs increased both with the number of drugs and combined
preparations per prescription. Acetylsalicylic acid and salbutamol were the most frequently prescribed drugs contributing to clinically
important DDIs. Additionally, acetylsalicylic acid and escitalopram, which interact with each other, were found on the list of Beers
criteria. The most predicted clinical outcomes of DDIs were increase in therapeutic efficacy and adverse/toxic reactions.
Conclusions: Prediction of DDIs in elderly patients will provide better prescribing and drug safety. Use of nonsteroidal anti-inflammatory
agents, selective serotonin reuptake inhibitors, and beta-2 adrenergic receptor agonists should be closely monitored.
Key words: Polypharmacy, pharmacovigilance, drug safety, geriatrics

1. Introduction
Although combination therapies are generally used to
achieve better therapeutic results, drug–drug interactions
(DDIs) can lead to life-threatening adverse reactions (ADRs)
or therapeutic failure by changing the therapeutic efficacy of
drugs. DDIs have been reported to cause 4% of drug-related
emergency visits (1). Changes in the pharmacokinetic
properties of drugs may produce adverse drug reactions
or therapeutic failure. The pharmacodynamics of
DDIs can produce additive, synergistic, or antagonistic
pharmacological effects (2).
ADRs can be considered an important public
health problem, particularly in the elderly patients
(3). Polypharmacy and DDIs play critical roles in the
production of ADRs and are related to an increased risk
of mortality (4,5). Among identified adverse drug events,
preventable adverse drug events have been reported to be
27% in primary care and 42% in long-term care, where
prescribing and monitoring stages of pharmaceutical care
were emphasized for prevention of adverse drug events
* Correspondence: mgfarma@gmail.com

(6,7). Potentially inappropriate medications have been
identified in Beers Criteria (8), which aimed to prevent poor
outcomes in elderly patients such as ADRs, hospitalization,
morbidity, or mortality (8). In the elderly population DDIs
can be diagnosed as severe adverse outcomes (9). Increased
sensitivity to DDIs in elderly patients and the most frequent
ADRs experienced by this age group have been shown
in many studies (10–12). Elderly patients exposed to
polypharmacy are at high risk of DDIs that depend on agerelated changes in pharmacokinetics or pharmacodynamics
of drugs, and multiple co-morbidities.
Another important factor for the increased vulnerability
of elderly patients to DDIs can be poor compliance, underuse,
overuse, or misuse of the medications (13). Moreover, elderly
patients who will undergo surgical treatment or treatment
in an intensive care unit have been reported to have a high
risk for the occurrence of DDIs (14). Although there are
publications investigating the use of inappropriate drugs in
Turkish elderly patients (15,16), there are no data evaluating
potential DDIs in Turkish elderly patients.
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This study aimed to assess: 1) the prevalence of potential
DDIs in the elderly patients of an outpatient clinic in a
family practitioner center in İstanbul, Turkey; 2) the effects
of sex, age, number of drugs, and combined preparations
on the frequency of DDIs; 3) the most common drugs/
drug groups contributing to DDIs with different risk rating
categories and potentially inappropriate medications
according to Beers Criteria; 4) the clinically important
predicted outcomes associated with DDIs.
2. Materials and methods
This retrospective study was performed in the outpatient
clinics of the Adem Yavuz Family Practitioner Center in
İstanbul, where 8 family practitioners serve a population
of approximately 32,000 patients. All units of the center
use Server AHBS family practitioners information
software for prescriptions, diagnoses, and demographical
data of the patients. Elderly patients (aged 65 or older, n
= 1206) who had consulted our medical center between
the dates of 01.11.2010 and 01.11.2011 were included.
This time period was chosen because it was the time
when the family practitioner system was officially started
in Turkey. The prescriptions (n = 5059) of the elderly
patients were examined for possible DDIs. There is
no data management system to check the DDIs in our
center. DDIs were determined by the following databases:
Micromedex Health Care Series Volume 148, Rx Media
2013, Lexi Comp’s Drug Information Handbook 19th
Edition, Lexi-Interact Online interactions checker, and
PubMed. The clinical severity of DDIs was classified as
an A, B, C, D, or X risk rating category according to the
Lexi-Interact Online database system (Table 1) (2). The
potentially inappropriate medications on the list of the
most frequently prescribed drugs contributing to DDIs
were detected according to Beers Criteria (8). The data
were processed for statistical analysis using the Mann–
Whitney U, Spearman, or Kruskal–Wallis test with SPSS
version 17.0. Approval for the study was obtained from the
Marmara University Ethical Committee (09.2012.0025).
3. Results
Of the 1206 elderly patients 61% were female. The mean
age of the patients was 72.9 ± 6.2 years. The total number
of drugs prescribed for female patients (n = 730) was 9123,
whereas male patients (n = 246) had 5308 drugs on their
prescriptions. There were 374 different diagnoses classified
according to the ICD-10-CM coding system on the
prescriptions of the patients. The most frequent diagnoses
were classified as follows: cardiovascular system diseases
(ICD-10-CM/I) (20%), musculoskeletal and connective
tissue diseases (ICD-10-CM/M) (15%), and digestive
system diseases (ICD-10-CM/K) (14.4%). Among 83.7%
of the prescriptions there were at least two drugs that could
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be analyzed for potential DDIs. There were 972 drugs with
different generic names and 542 drugs with different active
ingredients in the 4872 prescriptions with at least one
drug. The minimum, median, and maximum number of
drugs in a single prescription was 1, 3, and 10, respectively.
The most frequently prescribed drugs are shown in Table 2.
Of the 1206 patients, 54.7% had potential DDIs.
Among 5059 prescriptions written for the 1206 elderly
patients, 1670 (33%) were found to cause potential DDIs,
with 19.6% having one DDI and 13.4% having more
than one DDI. The total number of DDIs among the
5059 prescriptions was 3210. When these were analyzed
we detected 29 (0.9%) in the A risk rating category, 380
(11.8%) in the B risk rating category, 2494 (77.7%) in
the C risk rating category, 289 (9%) in the D risk rating
category, and 18 (0.6%) in the X risk rating category of
DDIs. Table 3 presents the 5 most frequently prescribed
drugs contributing to DDIs. Acetylsalicylic acid was the
most frequently prescribed drug contributing to the A,
C, and D risk rating category DDIs, whereas amlodipine
besilate was the most frequently prescribed drug for the
B risk rating category DDIs and it was salbutamol for the
X risk rating category DDIs. The number of prescriptions
and number of potential DDIs were analyzed in female
and male patients in order to investigate the effect of sex
on the frequency of DDIs (using P < 0.01, Mann–Whitney
U test). Although both female and male patients were
on polytherapy with drugs that may result in clinically
relevant DDIs, the number of DDIs was significantly
higher in the female patients than in the male patients
(Table 4). A statistically significant difference was found in
the number of interactions between different age groups
(Table 4). Elderly patients aged between 65 and 72 years
had significantly higher number of DDIs than did the
older age (81–88 years) group (P < 0.01, Kruskal–Wallis
statistics). The relationship between the number of drugs
per prescriptions and DDIs was analyzed. A greater
number of drugs on the prescriptions caused significantly
more potential DDIs (P < 0.01, Spearman’s rho = 0.524).
The percentage of DDI occurrences was 70% and higher
in the patients with at least 7 drugs on their prescriptions.
The number of potential DDIs was also compared
between prescriptions with or without combined drug
preparations. Of the 2649 prescriptions with combined
preparations, 2256 (70.3%) were found to have potential
DDIs, whereas the percentage of prescriptions with
DDIs was 29.7 for the prescriptions without combined
preparations (n = 2410) (P < 0.001, Mann–Whitney
U test). Mostly antihypertensive agents in combined
preparations such as valsartan/hydrochlorothiazide or
ramipril/hydrochlorothiazide had a C risk rating DDI
with NSAIDs or antidiabetics, which can cause a decrease
in antihypertensive effect and hypoglycemic effect or
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Table 1. Lexi-Interact Online DDI risk rating category.
Risk
Rating
A
B

C

D

X

ACTION

DESCRIPTION

No Known Interaction

Data have not demonstrated either pharmacodynamic or pharmacokinetic
interactions between the specified agents

No Action Needed

Data demonstrate that the specified agents may interact with each other, but there
is little to no evidence of clinical concern resulting from their concomitant use.

Monitor Therapy

Data demonstrate that the specified agents may interact with each other in a
clinically significant manner. The benefits of concomitant use of these two
medications usually outweigh the risks. An appropriate monitoring plan should
be implemented to identify potential negative effects. Dosage adjustments of one
or both agents may be needed in a minority of patients.

Consider Therapy Modification

Data demonstrate that the two medications may interact with each other in a
clinically significant manner. A patient-specific assessment must be conducted to
determine whether the benefits of concomitant therapy outweigh the risks.
Specific actions must be taken in order to realize the benefits and/or minimize
the toxicity resulting from concomitant use of the agents. These actions may include
aggressive monitoring, empiric dosage changes, choosing alternative agents.

Avoid Combination

Data demonstrate that the specified agents may interact with each other in a
clinically significant manner. The risks associated with concomitant use of these
agents usually outweigh the benefits. These agents are generally considered
contraindicated.

an increase in the adverse/toxic reactions of NSAIDs.
Additionally some of the most frequently prescribed
drugs such as the NSAIDs acetylsalicylic acid, diclofenac,
and etodolac and one of the most frequently prescribed
drugs contributing to DDIs, escitalopram, were found to
be on the list of potentially inappropriate medications of
Beers Criteria. An interaction that can lead to an increase

Table 2. The most frequently prescribed 10 drugs, number of
times, and percentages they have been detected in all analyzed
prescriptions (n = 5059).
Drugs

(n)

(%)

Paracetamol

736

3.8

Diclofenac sodium

680

3.5

Hydrochlorothiazide

529

2.7

Acetyl salicylic acid

326

1.7

Ibuprofen

325

1.7

Pseudoephedrine hydrochloride

313

1.6

Lansoprazole

311

1.6

Flurbiprofen

305

1.6

Vitamin B6

293

1.5

Etodolac

291

1.5

in bleeding and clotting disorders was detected between
acetylsalicylic acid and escitalopram.
The predicted clinical outcomes among the most
frequently prescribed drugs that contribute to DDIs are
indicated in Table 5 with examples for each risk rating
category DDI. The predicted clinical outcomes of the
potential DDIs were evaluated according to the risk rating
categories of the DDIs. Increase in therapeutic drug effect,
which was mostly identified under C risk rating category
DDIs, was the most frequently predicted clinical outcome
among the whole group of expected therapeutic results
related to various types of DDIs (Table 6). Increases
in adverse or toxic reactions were the most frequently
predicted clinical outcomes for the D and X risk rating
category DDIs (Table 6).
4. Discussion
The results of this study not only show the prevalence of
potential DDIs in elderly patients but also give valuable
information about the most frequently prescribed
drugs having a potential to generate DDIs in this
population. Further, this study indicates the impacts of
the demographical characteristics of patients, number
of drugs, or combined preparations per prescription on
the occurrence of DDIs in elderly patients. More than
half of the patients (54.7%) had potential to be exposed
to DDIs. Of the 5059 prescriptions, 33% were found to
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Table 3. The frequency of the most prescribed 5 drugs which contribute to DDIs are shown for each of drug interaction risk rating
category.
DDI risk
rating
category

1

%

2

%

3

%

4

%

5

%

A

Acetyl
salicylic acid

7.7

Hydrochlorothiazide

6.0

Heparins

4.7

Spironolactone

4.7

Amlodipine
besilate

3.7

B

Amlodipine
besilate

5.7

Hydrochlorothiazide

4.1

Diclofenac
sodium

3.3

Gliclazide

3.3

Etodolac

2.5

C

Acetyl
salicylic acid

4.4

Diclofenac sodium

4.4

Etodolac

2.7

Escitalopram
oxalate

2.4

Flurbiprofen

2.4

D

Acetyl
salicylic acid

5.2

Diclofenac sodium

4.5

Etodolac

3.2

Escitalopram
oxalate

2.9

Flurbiprofen

2.9

X

Salbutamol
sulfate

12.7 Tiotropium

7.8

Ipratropium
bromide

6.9

Budesonide

4.9

Formoterol

4.9

Table 4. The effects of sex and age on the number of prescriptions and number of potential DDIs.
Patients
(n)

Number of
prescriptions

Number of
DDIs

Number of
DDIs/number of
prescriptions (%)

Male

476

1924

1151

59.8

Female

730

3135

2059

65.7

Total

1206

5059

3210

65–72

592

2743

1564*

57.0

73–80

400

1627

1151

70.7

81–88

195

644

463

71.9

89–96

19

45

32

71.1

Total

1206

5059

3210

Characteristics
of patients
Sex

Age (years)

*, P < 0.01(different from older age group, 81–88 years).

have potential DDIs. Both sex and age were related to the
number of DDIs. The frequency of DDIs both increased
with the number of drugs per prescription and with the
existence of combined preparations in the prescriptions.
Acetylsalicylic acid was the most frequently prescribed
drug contributing to the clinically important C and D risk
rating category DDIs, whereas salbutamol was the most
frequently prescribed drug relevant to the X risk rating
category DDIs. Increase in therapeutic drug effect and
increase in adverse/toxic reactions were the most critical
predicted outcomes associated with potential DDIs.
It has been shown that as the number of elderly
patients with polypharmacy increases (17) the probability
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of poor outcomes related to clinically relevant DDIs
leading to ADRs or therapeutic failures becomes a vital
issue for public health. Elderly patients can be considered
a much more susceptible population than adult patients
to develop ADRs due to age dependent physiological
changes in the pharmacodynamic and pharmacokinetics
of drugs, to polypharmacy being prescribed, and to comorbid diseases. Although there are studies investigating
inappropriate drug use for Turkish elderly patients
(15,16), this is the first study evaluating the potential of
DDIs in Turkish elderly patients in an outpatient setting in
family practice systems. Various findings of other studies
evaluating DDIs in different elderly populations need to
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Table 5. DDI risk categories and predicted clinical outcomes among the most frequently prescribed drugs that contribute to DDIs.
Drugs/risk categories

Drugs contributing to DDIs

Predicted clinical outcome

C

acarbose, gliclazide, insulin

increase in hypoglycemic effect of acarbose

C

ramipril, furosemide

decrease in antihypertensive effect

C

sertraline

increase in antiplatelet activity, bleeding and clotting disorders

C

doxycycline

decrease in therapeutic efficacy of doxycycline

C

methylprednisolone, betamethasone

increase in adverse/toxic reactions of steroids

D

etodolac, ibuprofen, naproxen, diclofenac

increase in antiplatelet activity, bleeding and clotting disorders

D

warfarin

increase in anticoagulant activity, bleeding and clotting disorders

C

dexketoprofen

increase in antiplatelet activity, bleeding and clotting disorders

C

hydrochlorothiazide

decrease in antihypertensive effect

C

digoxin

increase in adverse/toxic reactions of digoxin

D

acetylsalicylic acid, escitalopram

increase in antiplatelet activity, bleeding and clotting disorders

D

escitalopram

decrease in therapeutic efficacy of escitalopram

C

flurbiprofen

increase in antiplatelet effect, bleeding and clotting disorders

D

acetylsalicylic acid, escitalopram

increase in antiplatelet effect, bleeding and clotting disorders

C

acetylsalicylic acid, enoxaparin

increase in antiplatelet effect, bleeding and clotting disorders

D

flurbiprofen, meloxicam, naproxen

increase in antiplatelet effect, bleeding and clotting disorders

tizanidine, famotidine, formoterol

QT prolongation, unwanted/life-threatening ventricular arrhythmias

C

carvedilol, metoprolol

decrease in antihypertensive effect

D

acetylsalicylic acid

increase in antiplatelet effect, bleeding and clotting disorders

propranolol, carvedilol

decrease in bronchodilatory effect of salbutamol

ipratropium

increase in anticholinergic effect

tiotropium

increase in anticholinergic effect

beta blockers (propranolol)

decrease in bronchodilatory effect of salbutamol

Acetylsalicylic acid

Diclofenac

Etodolac

Escitalopram

Flurbiprofen

Salbutamol
X
Tiotropium
X
Ipratropium
X
Formoterol
X

be considered. A study organized in an outpatient setting
in the US showed that 2.58% of visits with at least one
prescription had one or more DDI. In the same study, the
relationship between the number of drugs and occurrence
of DDIs was demonstrated and the most frequently
prescribed drug (6.60%) contributing to clinically relevant
DDIs was warfarin (18). Leone et al. (19), using an Italian
spontaneous reporting database, reported that 21.7% of
the reports included ADRs associated with DDIs. In the
same study, the percentage of reports with potential DDIs

showed an increase with the number of concomitantly
administered drugs and with an increase in the percentage
of male patients. The reports of elderly patients with 8
or more medications had a high percentage (88.3%) of
potential DDIs (19). Two/thirds (65%, n = 229) of the
ambulatory elderly patients in Nigeria were reported to
have potential DDIs. The risk of occurrence of DDIs was
found to be significantly higher in female patients and
patients with at least 6 medications on their prescriptions.
Angiotensin-converting enzyme inhibitors were the most
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Table 6. The number of the most frequently predicted clinical outcomes related to different risk rating category DDIs.
Predicted clinical outcomes

A

B

C

D

X

Total

Bleeding and clotting disorders

-

7

473

171

-

651

Decrease in therapeutic effect

-

226

590

35

2

853

Increase in therapeutic effect

-

109

707

20

Increase in adverse/toxic reactions

-

29

663

57

16

765

Increase/decrease in absorption of drug

-

16

11

3

-

30

Induction/inhibition of microsomal hepatic enzymes

-

-

40

5

-

45

Increase/decrease in elimination

-

-

5

-

-

5

P-glycoprotein mediated interactions

-

-

12

-

-

12

No interaction

29

-

-

-

-

29

Total number of various predicted clinical outcomes

29

387

2501

291

18

3226

frequently interacting drug group (20). In a main hospital
in Italy, the contribution of DDIs to ADRs was explored
in elderly patients. Of the 1054 Italian patients, 343 were
found to be affected by ADRs, particularly warfarin,
acenocumarol, and allopurinol. The total number of DDIs
was 912, of which 31.5% of them potentially contributed
to ADRs (21). These various findings may depend on
distinct therapeutic regimens in different countries
and ethnic differences in drug response of the patients.
Therefore national literature sources, indicating the most
common inappropriate drugs or drug combinations, play
an important role in the development of quality of life of
elderly patients.
We found that acetylsalicylic acid and salbutamol were
the most commonly prescribed drugs contributing to
clinically important C, D, and X risk rating category DDIs.
A well-known D risk rating category DDI is between
acetylsalicylic acid and nonsteroid anti-inflammatory
drugs (NSAIDs) or vitamin K antagonists such as warfarin.
Toxicity in the upper gastrointestinal tract is a serious
effect of NSAIDs (22) and concomitant use of salicylates
and NSAIDs or anticoagulants can increase the risk of
gastrointestinal bleeding (23,24). Moreover, combination
therapies of NSAIDs and steroids or antidepressants can
lead to unwanted bleeding reactions (22,25). Prophylactic
therapy with gastroprotective agents is recommended for
patients who have to be treated with these combination
therapies (22). Salicylates can diminish the antihypertensive
effect of angiotensin converting enzyme (ACE) inhibitors
(26). This C risk rating category DDI requires the blood
pressures of the patients to be closely monitored in order to
adjust for the effect of ACE inhibitors. Another important
C risk rating category DDI of acetylsalicylic acid has been
reported for hypoglycemic agents. Salicylates were shown
to enhance the effect of drugs lowering blood glucose
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levels (27). Therefore the blood glucose of patients should
be followed closely for dose adjustments of these agents.
The bronchodilatory effects of salbutamol, an adrenergic
beta-2 receptor agonist, can be antagonized by adding
beta-receptor blockers to the therapy. This DDI in the X
rating category is contra-indicated according to the LexiInteract Online database. Patients on therapy with betareceptor agonists are recommended to avoid taking betareceptor blockers (28).
One of the interesting findings of this study concerned
the most frequently prescribed drugs, NSAIDs such as
diclofenac sodium, acetyl salicylic acid, flurbiprofen,
and etodolac. These were detected not only to be among
the most frequently prescribed drugs but also the most
frequently prescribed drugs contribute to the clinically
important DDIs in the C and D risk rating category.
Moreover, some of the most frequently prescribed drugs
were found to be on the list of potentially inappropriate
medications of Beers Criteria (8). In this guideline
avoidance of chronic use of NSAIDs was recommended
in order to prevent the risk of gastrointestinal bleeding
and peptic ulcer diseases, particularly in patients aged >75
years (8). NSAIDs were also shown to be the most common
inappropriately used drug group in Turkish elderly patients
(16). Therefore prescription of NSAIDs should be checked
in order to improve prescribing and drug safety in elderly
patients. Table 3, listing the most frequently prescribed
drugs contributing to DDIs, shows that escitalopram, a
selective serotonin re-uptake inhibitor (SSRI), is on the
list of Beers Criteria. SSRIs are potentially inappropriate
medications that should be used with caution due to the
risk of inappropriate antidiuretic hormone secretion or
hyponatremia (8). According to our results, escitalopram
was involved in the DDI of D risk rating category, which
needs to be closely monitored in patients. Concurrent use
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of SSRIs and carbamazepine can lead to carbamazepine
toxicity (29). Moreover, combinations of SSRIs and lithium
can cause a serotonin syndrome (30).
The lack of information about clinical outcomes in
elderly patients associated with DDIs in our study may be
its most important limitation. Although the frequency of
the use of inappropriate drug combinations with NSAIDs,
salbutamol, tiotropium, budesonide, or ipratropium was
found to be high, the patients could not be checked for the
therapeutic results of the DDIs. Nor could we determine
even the most frequently predicted clinical outcomes. The
clinical relevance of these interactions should be checked
in order to provide evidence-based therapies. Another
limitation may be the generalization of our data to the
whole country. The patients of only one outpatient clinic
in İstanbul participated in this study. However, our data
can be considered to reflect the general population due to
the cosmopolitan structure of İstanbul with diverse people
from all over the country. This study is the first one on

DDIs in outpatient clinics among Turkish elderly patients
and further studies including more than one outpatient
clinic in different cities in Turkey should be planned for
improving the quality of life of patients in the older age
group.
This study shows that clinically relevant DDIs that
may need therapeutic modification are fairly common
in elderly patients in outpatient clinics in Turkey. The
prescription of NSAIDs, escitalopram, and the drugs in
the contraindicated combination therapies (salbutamol,
tiotropium, and ipratropium) should be closely monitored
in elderly patients in order to prevent DDIs and optimize
the management of the medication in this older population.
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